SEC Form 4 · accession 0001171843-17-007020
Protara Therapeutics, Inc. · TARA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Garen G Bohlin
Director
Period of report
Nov 10, 2017
Accepted (ET)
Nov 14, 2017 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001359931
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Nov 10, 2017 | A | 23,800 | $1.963 | A | 23,800 | D | |
| Common StockF3 | Nov 13, 2017 | A | 25,700 | $1.918 | A | 49,500 | D | |
| Common StockF4 | Nov 14, 2017 | A | 3,812 | $1.889 | A | 53,312 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2017.
- F2The purchase price of $1.963 is reflective of the weighted average purchase price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.91 to $2.01. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The purchase price of $1.918 is reflective of the weighted average purchase price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.905 to $1.96. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The purchase price of $1.889 is reflective of the weighted average purchase price of all transactions reported on this line. The prices for the transactions reported on this line range from $1.71 to $1.911. The reporting person undertakes to provide Proteon Therapeutics, Inc., any security holder of Proteon Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.